TP-5809 / Sumitomo Pharma - LARVOL DELTA

[VIRTUAL] Elucidation of a unique regulatory mechanism for TNK1 provides potential therapeutic targeting opportunities in cancer (AACR 2021) - "TP-5809 also potently inhibits the in vitro growth of mutant TNK1-driven pro-B cells and reduces disease burden and prolongs survival in mice with xenografted tumors. Together, our data elucidate the first mechanism of TNK1regulation and identify lead compounds for the development of a TNK1 inhibitor."

Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • STAT5 • UBB

[VIRTUAL] TP-5809, a novel TNK1 inhibitor, suppresses TNK1 dependent signaling and tumor growth in a preclinical model of Hodgkin’s lymphoma (AACR 2021) - "We conclude that TP-5809 is a biologically active TNK1 inhibitor, which could allow further exploration of TNK1 as a clinically relevant therapeutic target in lymphoma and/or other TNK1-dependent cancers. Targeting aberrant TNK1 phosphorylation using TP-5809 can potently and specifically inhibit pathology driven by hyperactive and mutant forms of TNK1."

Preclinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • STAT3 • STAT5

Sumitomo Dainippon Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Virtual Annual Meeting I 2021 (PRNewswire) - "Sumitomo Dainippon Pharma Oncology, Inc...presented new findings on a range of investigational agents from the company's pipeline at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021. The data presented at the meeting include preclinical and Phase 1 clinical data evaluating the potential anti-cancer activity of the PKM2 activator TP-1454, PIM inhibitor TP-3654, TNK1 inhibitor TP-5809 and CDK9 inhibitor alvocidib."

P1 data • Preclinical • Hodgkin Lymphoma • Lymphoma • Oncology • Solid Tumor